CAS: 126544-47-6; 2-((6Ar,6Bs,7S,8As,8Bs,10R,11Ar,12As,12Bs)-10-Cyclohexyl-7-Hydroxy-6A,8A-Dimethyl-4-Oxo-1,2,4,6A,6B,7,8,8A,11A,12,12A,12B-Dodecahydro-8Bh-Naphtho[2',1':4,5]Indeno[1,2-D][1,3]Dioxol-8B-yl)-2-Oxoethyl Isobutyrate

上下游产品

CAS号2043-61-0 环己烷甲醛 | CAS号996-30-5 异丁酸钠 | CAS号19455-20-0 异丁酸钾 | CAS号25179-23-1 异丁酸锂 | CAS号60154-69-0 tetrabutylammon... | CAS号161115-59-9 去异丁基环索奈德 | CAS号97-72-3 异丁酸酐 | CAS号161115-59-9 去异丁基环索奈德

16-α Hydroxyprednisonlone Acetate置于甲醇,氢溴酸,Potassium Carbonate,Sodium Hydroxide体系中,用 二氯甲烷,N,N-二甲基甲酰胺 用作溶剂,化学反应 9.0H,反应生成环索奈德
参考文献:一种环索奈德的制备方法
标题:一种环索奈德的制备方法
摘要:本发明公开了一种环索奈德的制备方法,包括以下步骤:缩醛反应,第一次提纯,水解反应,酯化反应和第二次提纯;缩醛反应:将16α‑羟基泼尼松龙‑21‑醋酸酯加入极性溶剂中,搅拌溶解后,控温至合适的温度,之后加入酸催化剂,控制反应温度在合适的范围内,保温在合适的温度,反应完全后,得到缩合反应得到缩醛物(1)(R/s=90:10).本发明选择16α‑羟基泼尼松龙‑21‑醋酸酯为起始原料,经过16,17位以及21位的改造,异构体的分离,可以得到纯度较高的环索奈德,同时采用公司现有的中间体为起始原料,线路稳定易控,从中间体阶段控制r/s配比,大大减少纯化过程的损失,收率及成本明显优于其他合成方法.

专利信息

专利号:US-2025206743-A1
优先权日:2022-03-25
标 题:Tyk2 inhibitor synthesis and intermediates thereof
发明人：MASSE CRAIG E; PHADKE AVINASH S; LAWSON JON P; LEVY STUART; YANG XIAOWEI; WU GUISHENG; FAN SHUFENG
权利人:TAKEDA PHARMACEUTICALS CO
摘要:Described herein are methods of synthesis of a tyrosine-protein kinase 2 (TYK2) inhibitor and to intermediate compounds of the synthesis and methods of making the intermediates. Also provided are pharmaceutically acceptable compositions including compounds prepared by the synthetic method and methods of treating disorders using the same.

专利号:US-8158780-B2
优先权日:2006-09-19
标 题:Processes for the preparation of ciclesonide and its crystal modification
发明人：PHULL MANJINDER SINGH; RAO DHARMARAJ RAMACHANDRA; KANKAN RAJENDRA NARAYANRAO
权利人:PHULL MANJINDER SINGH; RAO DHARMARAJ RAMACHANDRA; KANKAN RAJENDRA NARAYANRAO; CIPLA LTD
摘要:Improved processes for the synthesis of ciclesonide, chemically termed as [11β,16α(R)]-16,17-[(cyclohexylmethylene)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)pregna-1,4-diene-3,20-dione and its crystal modification.

专利号:US-10906888-B2
优先权日:2016-07-14
标 题:Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme
发明人：CASIMIRO-GARCIA AGUSTIN; STROHBACH JOSEPH WALTER; HEPWORTH DAVID; LOVERING FRANK ELDRIDGE; CHOI CHULHO; ALLAIS CHRISTOPHE PHILIPPE; WRIGHT STEPHEN WAYNE
权利人:PFIZER
摘要:Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

专利号:US-9982006-B2
优先权日:2014-08-21
标题:2′-chloro aminopyrimidinone and pyrimidine dione nucleosides
发明人：CLARKE MICHAEL O'NEIL HANRAHAN; MACKMAN RICHARD L; SIEGEL DUSTIN
权利人:GILEAD SCIENCES INC
摘要:Provided herein are formulations, methods and substituted 2′-chloro aminopyrimidinone and pyrimidine dione compounds of Formula (I) for treating Pneumovirinae virus infections, including respiratory syncytial virus infections, as well as methods and intermediates for synthesis of substituted 2′-chloro aminopyrimidinone and pyrimidine dione compounds.

专利号:US-2012015923-A1
优先权日:2009-03-24
标 题:Use of andrographolide compounds for treating inflammation and airway disorders
发明人：WONG WAI SHIU FRED
权利人:WONG WAI SHIU FRED; UNIV SINGAPORE
摘要:We describe for the first time that andrographolide derivatives such as DDAG effectively reduced OVA-induced inflammatory cell recruitment into BAL fluid, IL-4, IL-5, IL-13 and eotaxin production, serum IgE synthesis, pulmonary eosinophilia, mucus hypersecretion and AHR in a mouse asthma model potentially via inhibition of NF-?B activity. Moreover, low dose of DDAG and glucocorticoid combination treatment synergistically attenuate inflammation in mouse asthma model. These findings support a therapeutic value for DDAG in the treatment of asthma.

专利号:US-8697730-B2
优先权日:2007-10-26
标题 :5-lipoxygenase activating protein (FLAP) inhibitor
发明人：REWOLINSKI MELISSA VIRGINIA; SCHAAB KEVIN MURRAY; KING CHRISTOPHER DAVID; STOCK NICHOLAS SIMON
权利人:REWOLINSKI MELISSA VIRGINIA; SCHAAB KEVIN MURRAY; KING CHRISTOPHER DAVID; STOCK NICHOLAS SIMON; PANMIRA PHARMACEUTICALS LLC
摘要:Described herein are methods for the synthesis of 3-[5-(pyridin-2-ylmethoxy)-3-(2-methyl-2-propylthio)-1-[4-(2-methoxypyridin-5-yl)benzyl]-indol-2-yl]-2,2-dimethyl-propionic acid, pharmaceutically acceptable salts, pharmaceutically acceptable solvates thereof. Also described are pharmaceutical compositions suitable for oral administration to a mammal that include, as well as methods of using such oral pharmaceutical compositions for treating respiratory conditions or diseases, as well as other leukotriene-dependent or leukotriene mediated conditions or diseases.